- Trial Phase
- Preclinical (Phase 1 imminent)
- Time to Market
- Multiple years if successful. The drug has not yet entered Phase 1. Assuming positive Phase 1 results and a Phase 2 start in 2H 2027, Phase 3 trials would follow, putting a potential approval at earliest several years out (likely 2030+).
- Why 3/10
- The next hard catalyst is the start of Phase 1 clinical trials, expected in January 2027 (about two months away). However, EVO570 is preclinical and has not generated any human data yet, so Phase 1 initiation is a modest catalyst rather than a make-or-break binary event. After the EVO756 Phase 2b failure in atopic dermatitis (Sept 2026), EVO570 is strategically important for Evommune as a pipeline replenishment, but it is still very early stage, which limits the potential near-term stock-price impact to the 2-4 range on the impact score scale.
The key near-term event to watch is the formal announcement of Phase 1 first-patient-dosed (expected January 2027). A successful start would signal the molecule is safe enough for human testing. The more consequential catalyst will be Phase 1 safety and PK/PD data around mid-2027, which will provide the first human proof-of-mechanism for VAV1 degradation. Investors should also monitor how the Phase 2 Sjogren's data for Novartis' competing VAV1 degrader MRT-6160 reads out, as positive results would validate the target but also increase competitive pressure.
Price Chart
Executive Summary
EVO570 is an oral VAV1-directed molecular glue degrader licensed by Evommune (NYSE: EVMN) from China's Hinova Pharmaceuticals on November 4, 2026 for $30M upfront ($20M cash + $10M pre-funded warrants) and up to approximately $1.1B in milestones plus tiered royalties. The drug is still preclinical but was acquired to fill the pipeline gap after Evommune's lead candidate EVO756 failed a Phase 2b atopic dermatitis trial in September 2026. A Phase 1 study is expected to start in January 2027, with Phase 2 in rheumatoid arthritis planned for the second half of 2027. EVO570 enters a competitive space where Novartis (via Monte Rosa Therapeutics' MRT-6160/DDY391) already has a VAV1 degrader in Phase 2 testing for Sjogren's disease. Evommune concurrently raised $30M through a PIPE, extending its cash runway into the second half of 2029. The stock trades at ~$6.50, far below its $33.20 52-week high but above its $4.94 low, with a consensus analyst price target of $22 (median) and a 15 Buy/4 Hold recommendation split.
How It Works
EVO570 is an oral pill that works like "molecular glue" -- it sticks a protein called VAV1 to the cell's trash-disposal system so the cell destroys it. VAV1 is a signaling protein found mainly in immune cells (T cells and B cells) that helps drive inflammation in autoimmune diseases like rheumatoid arthritis. By degrading VAV1, EVO570 aims to dial down the overactive immune response.
Trial Status
EVO570 is still in preclinical development. Requests to begin clinical trials have been accepted in the US and submitted in China. A Phase 1 study is expected to begin imminently (reports point to January 2027), with initial data anticipated around mid-2027. Evommune plans to initiate a Phase 2 proof-of-concept trial in rheumatoid arthritis in the second half of 2027. Hinova Pharmaceuticals previously advanced the molecule through preclinical studies showing sub-nanomolar potency, high selectivity for VAV1, and activity in multiple autoimmune disease animal models (collagen-induced arthritis, T-cell transfer IBD, EAE multiple sclerosis model).
The Two-Sided Case
Upcoming Catalysts
- Phase 1 clinical trial initiation (expected early 2027 / January 2027)
- Phase 1 safety/pharmacokinetics/pharmacodynamics data readout (expected mid-2027)
- Phase 2 rheumatoid arthritis trial start (planned 2H 2027)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Evommune, Inc. 8-K EVMN ·Originating report